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Abstract
Background: In many rural areas of tropical countries such 
as Indonesia, the prevalence of soil-transmitted helminths 
(STH) infections remains high. At the same time, the burden 
of allergic disorders in such rural areas is reported to be low 
and inversely associated with helminth infections. To reduce 
the morbidity and transmission of helminth infections, the 
world health organization recommends preventive treat-
ment of school children by providing mass drug administra-
tion (MDA) with albendazole. Here, we had an opportunity 
to evaluate the prevalence of skin reactivity to allergens be-
fore and after albendazole treatment to get an indication of 
the possible impact of MDA on allergic sensitization. Meth-
ods: A study was conducted among 150 school children liv-
ing in an area endemic for STH infections. Before and 1 year 
after anthelminthic treatment with albendazole, stool sam-
ples were examined for the presence of STH eggs, skin prick 
tests (SPT) for cockroach and house dust mites were per-
formed, blood eosinophilia was assessed, and total immuno-
globulin E (IgE) and C-reactive protein (CRP) were measured 
in plasma. Results: Anthelminthic treatment significantly re-
duced the prevalence of STH from 19.6 before treatment to 
6% after treatment (p < 0.001). Levels of total IgE (estimate: 
0.30; 95% CI 0.22–0.42, p < 0.0001), CRP (estimate: 0.60; 95% 
CI 0.42–0.86, p = 0.006), and eosinophil counts (estimate: 
0.70; 95% CI 0.61–0.80, p < 0.001) decreased significantly. 
Steven L. Staal, Sarika K.L. Hogendoorn, Sophie A. Voets, Rebecca C. 
Tepper, Mirte Veenstra, Ivo I. de Vos, Koen C. van Son, and Jari K. Gool 
contributed equally to this work.
Edited by: I. Lehmann, Berlin.
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
tribution of modified material requires written permission.
Skin Reactivity to Allergens after 
Anthelminthic Treatment
193Int Arch Allergy Immunol 2018;177:192–198
DOI: 10.1159/000490952
The prevalence of SPT positivity increased from 18.7 to 
32.7%. Multivariate analysis adjusted for confounding fac-
tors showed an increased risk of being SPT positive to any 
allergen (OR 3.04; 95% CI 1.338–6.919, p = 0.008). Conclu-
sions: This study indicates that 1 year of MDA with albenda-
zole was associated with a reduced prevalence of STH infec-
tions. This study shows that the prevalence of allergic sensi-
tization increases after 1 year of albendazole treatment. 
Placebo-controlled and larger studies are needed to further 
substantiate a role of deworming treatment in an increased 
risk of allergic sensitization. © 2018 The Author(s)
Published by S. Karger AG, Basel
Introduction
Allergic diseases are a major global health burden and 
their prevalence is increasing. Worldwide, 20–30% of the 
global population suffers from some form of allergy [1] 
with notably higher rates of such immune disorders in 
industrialized nations [2]. On a smaller scale, communi-
ties in low- and middle-income countries transitioning 
from rural to urban settings are also experiencing an in-
crease in the frequency of allergic diseases [3].
According to the “hygiene hypothesis,” first coined by 
Strachan in 1989, the prevalence of allergic disease will 
increase if there is a decreased exposure to common in-
fectious diseases in early life or a decreased diversity of 
infectious agents is encountered [4–6]. Epidemiological 
studies examining the relationships between helminth in-
fections, which are highly prevalent in low-income coun-
tries, and allergic disorders have provided evidence for an 
inverse association between helminth infections and al-
lergic disorders [3, 7, 8]. The strongest evidence for the 
association between helminth infections and allergy has 
been provided by small intervention studies that have 
shown increases in the prevalence or the risk of atopy af-
ter anthelmintic treatment of infected children [9, 10]. 
However, there are also studies showing no or a positive 
association between helminths and allergies, indicating 
that other factors, such as lifestyle, can play an essential 
role in the pathogenesis of allergies [11–13].
As in the case of allergic disorders, chronic helminth 
infections induce a strong T-helper 2 (Th2) immune re-
sponse that leads to elevated levels of immunoglobulin E 
(IgE), eosinophils, basophils, and mast cells [8, 14]. How-
ever, unlike immune responses induced by allergens, hel-
minth infections also lead to increased anti-inflammatory 
cytokines, such as interleukin (IL-10) and transforming 
growth factor-β [5, 16]. The anti-inflammatory environ-
ment induced by chronic helminth infections can spill 
over to third party antigens, thereby attenuating the re-
sponsiveness to “bystander antigens” including a de-
creased reactivity to allergens [17], and it thus results in a 
decreased prevalence or risk of atopy and allergic disor-
ders.
Indonesia, a country in economic transition, is also ex-
periencing a steady increase in the prevalence of allergic 
disorders [15, 18] in the face of a decreasing prevalence of 
helminth infections due to health education, changes in 
lifestyle, improvements in sanitation, and mass drug ad-
ministration (MDA) [19]. As school-based MDA pro-
grams are increasingly advocated and implemented by 
the Indonesian government, there is a window of oppor-
tunity to investigate the effect of MDA with albendazole 
on the prevalence of SPT reactivity to allergens in school 
children in Indonesia.
Methods
Study Population and Design
This study was performed in an elementary school (SD Katolik 
Nangamboa) in the Nangapanda Village, Ende District, Flores Is-
land, Indonesia. The study site was selected on the basis of a high 
prevalence of soil-transmitted helminths (STH) [20]. Data were 
collected in October 2015 and October 2016. Prior to this study, 
written informed consent was obtained from the parents/legal 
guardians of the children. Approval was obtained from the ethical 
committee of the Faculty of Medicine of the University of Indone-
sia (Jakarta, Indonesia; approval No. 194/PT2.FK/ETIK/2006 and 
825/UN2.F1/ETIK/2016). In total, 150 children were included in 
this study. 
Anthelminthic Treatment
As part of the school-based MDA program, school children 
were treated with a single dose (400 mg) of albendazole biannu-
ally in October 2015 and March 2016. 
Data Collection
A standardized questionnaire was used to assess general popu-
lation characteristics including date of birth and gender. The ques-
tionnaire was administered face-to-face by one researcher accom-
panied by a teacher. 
Body height and weight were measured using a portable stadi-
ometer (SECA model 213; Seca GmbH & Co., Hamburg, Germa-
ny) and a mobile flat scale (SECA model 876; Seca), respectively 
[21].
Infections with STH, Ascaris lumbricoides, Trichuris trichiura, 
and hookworm were examined via 2 Kato-Katz smears from 1 
fresh stool sample [22]. 
Regarding allergy outcomes, SPT reactivity was examined 
against allergen extracts of cockroach (Blatella germanica) and 2 
species of Dermatophagoides house dust mites (D. pteronyssinus 
and D. farinae; ALK-Abello BV, Almere, The Netherlands). Hista-
mine chloride and allergen diluents were used as positive and neg-
Staal et al.Int Arch Allergy Immunol 2018;177:192–198194
DOI: 10.1159/000490952
ative controls, respectively. SPT was performed on the volar side 
of the lower arm and the results were measured after 15 min. SPT 
reactivity was considered positive if the longest diameter plus the 
perpendicular diameter of the wheal divided by 2 was at least 
3 mm. 
To assess eosinophil counts, a Giemsa-stained thin-blood 
smear was made from finger prick blood and eosinophil counts 
were expressed in percentages. 
Levels of plasma C-reactive protein (CRP) were measured us-
ing commercial reagents (DuoSet ELISA, R&D Systems Europe, 
Ltd., Abingdon, UK), according to the manufacturers’ protocol. In 
brief, mouse anti-human CRP capture antibody was coated over-
night on MaxiSorp plates. Diluted capillary plasma (1: 10,000) was 
added to the wells and incubated at room temperature for 2 h, fol-
lowed by a second biotinylated mouse anti-human CRP detection 
antibody. After washing, plates were incubated with streptavidin-
HRP for 20 min. The colour was developed with tetramethylben-
zidine and stopped with 10% H2SO4. A serial human CRP standard 
with a limit of detection of 15.6 pg/mL was included in each plate 
to calculate the CRP concentration of the samples. The results were 
expressed in milligrams per liter. 
Total IgE levels were measured as previously described [23]. 
Briefly, MaxiSorp plates were coated overnight with rabbit anti-
human IgE (Dako, Glostrup, Denmark). Plates were blocked with 
phosphate-buffered saline containing 5% bovine serum albumin 
(Albumin Fraction V; Boehringer, Mannheim, Germany). Capil-
lary plasma was diluted (1: 100) in phosphate-buffered saline con-
taining 0.05% Tween-20 and added to the wells. As a reference, the 
WHO standard of human serum IgE (NIBSC, Potters Bar, UK) was 
used, starting at a concentration of 90 IU/mL with a limit of detec-
tion of 0.04 IU/mL. Plates were incubated for 1 h and, after a wash-
ing step, IgE biotinylated goat anti-human IgE antibody (Vector 
Laboratories, Burlingame, CA, USA) was added and incubated for 
1 h, followed by incubation with streptavidin alkaline phosphatase 
conjugate (Boehringer). The colour was developed by addition of 
para-nitrophenylphosphate (Boehringer) diluted in diethanol-
amine buffer, and optical density was measured at 405 nm. The 
results were expressed in International Units per milliliter. 
Statistical Analysis
Descriptive data was analysed using IBM SPSS Statistics ver-
sion 23 (IBM Inc., USA) and expressed as medians (IQR) or fre-
quencies (% of collected data). Continuous data were log-trans-
formed to obtain normally distributed variables. Changes in out-
comes between 2 time points (before and after MDA) were assessed 
using linear mixed models with subject random effects. For con-
tinuous variables, parameter estimates (95% CI) were reported. 
The reported P values were obtained using a likelihood ratio test 
comparing the model with and without a time effect. For the bi-
nary outcomes, a logistic model was used with random subject ef-
fects. All models were fitted using the lme4 package (R software 
version 3.1.3) and the scripts are given in the online supplemen-
tary Methods (see www.karger.com/doi/10.1159/000490952 for 
all online suppl. material). 
Results
Study Population
The baseline characteristics of the 150 participants are 
shown in Table 1. The age of the children ranged from 7 
to 15 years, with a mean age of 10.1 years; 51.3% of the 
children were male. At baseline 19.6% of the children 
were infected with 1 or more helminth species; T. trichi­
ura was the predominant species (11.2%), followed by A. 
lumbricoides (8.4%) and hookworm (4.9%). Among the 
28 helminth-infected subjects, 7 (25%) had multiple hel-
minth infections. The prevalence of SPT reactivity to any 
allergen at baseline was 18.7%, with 17.3% being positive 
to cockroach and only 2.7% being positive to any house 
dust mite (Table 1).
Prevalence of STH Infection after MDA 
One year after MDA, 113 out of 150 children returned 
for follow-up and stool samples were available from 102 
children. Following anthelminthic treatment, the preva-
lence of STH infections decreased significantly (Fig. 1). 
For any helminth, the prevalence decreased from 19.6 to 
5.9%, for A. lumbricoides it decreased from 8.4 to 1.0%, 
for T. trichiura it decreased from 11.2 to 3.9%, and for 
hookworm it decreased from 4.9 to 1.0% (all p < 0.001). 
Changes in Immune Parameters following MDA
Changes in immune parameters following MDA were 
assessed using a linear mixed model adjusting for age and 
sex. The results in Table 2 show that all immune param-
eters measured in the total population, including total IgE 
Table 1. Characteristics of the study population at baseline
Parameter Value
Age, years 10.1±1.5
Sex
Male 77 (51.3)
Female 73 (48.7)
STH infection (N = 143)
Any STH 28 (19.6)
A. lumbricoides 12 (8.4)
T. trichiura 16 (11.2)
Hookworm 7 (4.9)
Skin prick reactivity
Any allergen 28 (18.7)
B. germanica (cockroach) 26 (17.3)
House dust mite 4 (2.7)
D. pteronyssinus 4 (2.7)
D. farinae 3 (2.0)
Values are presented as numbers (%) or means ± SD. The total 
number of patients was 150 unless otherwise stated.
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(estimate: 0.30; 95% CI 0.22–0.42, p < 0.0001), eosino-
phils (estimate: 0.70; 95% CI 0.61–0.80, p < 0.001), and 
CRP (estimate: 0.60; 95% CI 0.42–0.86, p = 0.006) de-
creased significantly 1 year after MDA. Additionally, 
stratification analysis based on STH status at baseline 
showed that the changes in immune parameters over time 
did not differ between helminth-positive and helminth-
negative subjects (online suppl. Table S1).
SPT Reactivity to Allergens before and after MDA
Following MDA, SPT reactivity to allergens was as-
sessed in 113 children. The results show that the preva-
lence of SPT reactivity increased from 18.7 to 32.7% for 
any allergen, from 17.3 to 26.5% for cockroach, and from 
2.7 to 14.2% for any house dust mite 1 year after MDA. 
When species of house dust mites are considered, the re-
sults show that the prevalence of SPT increased from 2.7 
to 10.6% and from 2 to 4.4% for D. pteronyssinus and D. 
farinae, respectively. Multivariate analysis adjusting for 
age and sex showed that skin reactivity to any allergen 
(OR 3.04; 95% CI 1.338–6.919, p = 0.008) and to any 
house dust mite (OR 5.66; 95% CI 1.83–17.54, p = 0.003) 
but not to cockroach (OR 1.83; 95% CI 0.81–4.14, p = 
0.15) (Fig. 2) increased after MDA. The increased risk of 
skin reactivity to house dust mite allergens after MDA is 
mainly due to the increased risk of reactivity to D. ptero­
nyssinus (OR 4.38; 95% CI 1.36–14.14, p = 0.013) and not 
to D. farinae (estimate: 2.21; 95% CI 0.51–9.54, p = 0.29) 
(Fig. 2). Stratification analysis based on the STH status at 
baseline further showed that the prevalence of SPT reac-
tivity increased from 20.9% (24/115) to 34.1% (29/85) and 
from 3.6% (1/28) to 25% (6/24) in helminth-negative and 
helminth-positive subjects, respectively. Whereas a bor-
derline significant effect was seen in the helminth-posi-
tive subjects (OR 0.62; 95% CI 0.73–5.30, p = 0.05), in 
helminth-negative subjects MDA resulted in a significant 
increase in SPT reactivity (OR 2.41; 95% CI 1.06–5.51, 
p = 0.036).
Table 2. Changes in immune parameters following MDA in the total study population
Parameter Baseline Follow-up Estimate (95% CI) p value
Total IgE, IU/mL 667.87 (316.67–877.36)a 109.10 (27.90–628.17)c 0.30 (0.22–0.42) <0.0001
Eosinophil count, % 8 (5–11)b 5 (3–8)d 0.70 (0.61–0.80) <0.001
CRP, mg/L 1.71 (0.53–6.23)b 0.95 (0.11–3.47)c 0.60 (0.42–0.86) 0.006
Values are presented as medians (IQR) unless otherwise stated. Estimates and 95% CI are based on generalized linear mixed models from log-transformed 
data. Values shown are back-transformed. p values were generated using a likelihood ratio test comparing models with and without a time effect. a n = 146. 
b n = 150. c n = 112. d n = 111.
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Fig. 1. Helminth prevalence before and after MDA with albenda-
zole. Percentage of any helminth, A. lumbricoides, T. trichiura, and 
hookworm before and after MDA. MDA was associated with a 
significant decrease in the prevalence of any helminth, A. lumbri­
coides, T. trichiura, and hookworm. p values were calculated using 
a logistic model with subject random effects. * p < 0.001.
Fig. 2. Changes in SPT reactivity to allergens before and after MDA 
with albendazole. The risk of positive SPT reactivity following MDA 
is shown as OR with 95% CI calculated using a logistic model ad-
justed for age and sex. Of the 150 SPT-tested subjects before treat-
ment, SPT reactivity to any allergen, any house dust mite, D. ptero­
nyssinus, D. farinae, and cockroach was detected in 28 (18.7%), 4 
(2.7%), 4 (2.7%), 3 (2%), and 26 (17.3%) subjects, respectively. After 
anthelminthic treatment, SPT performed in 113 subjects showed 
that the number of subjects positive to any allergen, any house dust 
mite, D. pteronyssinus, D. farinae, and cockroach was 37 (32.7%), 16 
(14.2%), 12 (10.6%), 5 (4.4%), and 30 (26.5%), respectively.
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Discussion
STH infections are among the most prevalent infec-
tions in the world. MDA programs have become the most 
commonly used national intervention strategy in hel-
minth-endemic countries to achieve the goal of STH 
elimination [24]. For the deworming program in the 
Nangapanda community, the Indonesian government 
implements WHO guidelines [25] and provides albenda-
zole treatment to school children biannually. The results 
of this study show that treatment with albendazole led to 
a significant reduction in the prevalence of A. lumbricoi­
des, T. trichiura, and hookworm infections. 
The decrease in helminth prevalence after MDA was ac-
companied by a decrease in total IgE levels and eosinophil 
counts. These findings are in agreement with our previous 
results which showed that albendazole treatment leads to 
a decrease in total IgE levels [27–29]. Likewise, a school-
based cluster-randomized study in Ecuador observed a 
strong association between total IgE and STH infection but 
not with age, nutritional, or socioeconomic status, suggest-
ing that STH infection is an important determinant of total 
IgE [30]. With respect to the number of STH infections, 
Tahapary et al. [26] observed that the effect of albendazole 
treatment on total IgE levels and eosinophil counts was 
more pronounced in subjects with multiple helminth in-
fections compared to single or no infection. However, this 
was not observed in the current study, probably due to the 
lower STH prevalence and the small sample size.
The finding that the level of CRP, a marker of inflam-
mation, decreased after albendazole treatment is in con-
trast with our previously reported study conducted in 
adults (age ≥ 16 years) in the same area, which showed 
that albendazole treatment had no effect on high-sensitiv-
ity CRP levels [26]. Similarly, a study in Tanzanian school 
children infected with hookworm or Schistosoma haema­
tobium reported that albendazole or praziquantel treat-
ment had no effect on CRP levels [31]. Furthermore, a 
study conducted in an area endemic for helminths and 
malaria in Tanzania observed a strong association be-
tween CRP levels and malaria but not with helminth infec-
tions [32]. Although no information regarding malaria 
status was collected in the current study, from our previ-
ous studies in the area it is known that this area is endem-
ic for Plasmodium spp. [20]. Moreover, as we had no pla-
cebo arm to control for changes not related to MDA that 
occur in 1 year, we cannot rule out that changes in other 
exposures are associated with the change in CRP levels. 
In the stratification analysis, we did not observe larger 
changes in immune parameters following MDA in hel-
minth-positive compared to helminth-negative subjects, 
probably due to the small sample size. It should also be 
noted that the presence of STH infections was determined 
in a single stool sample by microscopy, which misses light 
infections and subsequently can misclassify STH status. 
Thus, deworming can have a much larger effect in the 
community than that which is detectable by assessing hel-
minth using microscopy. Moreover, as this is not a place-
bo-controlled trial, the effects could be due to other envi-
ronmental changes. Finally, there is also the possibility 
that albendazole affects macro- and microbiomes direct-
ly, which can affect the immune system [33–35].
In this study, the decrease in STH prevalence following 
MDA was accompanied by an increase in the prevalence of 
SPT reactivity, especially to the house dust mite D. ptero­
nyssinus. This is in line with the notion that chronic hel-
minth infection dampens excessive inflammatory respons-
es through the induction of a suppressive immune envi-
ronment [5]. Several other studies have shown a similar 
inverse relationship between STH infections and SPT re-
activity. A study in Gabon found that SPT reactivity was 
significantly reduced in children infected with S. haemato­
bium and/or filariae [36]. Similarly, a Venezuelan study in 
an area with a high STH infection prevalence found that a 
decrease in the prevalence of STH infections was accom-
panied by an increase in positive SPT reactivity to house 
dust mites [9]. Though not significant, our previous study 
conducted in children aged 5–19 years from neighbouring 
villages found an incremental increase in SPT positivity to 
allergens at 9 and 21 months after the initiation of treat-
ment [20]. It has to be noted that the reduction in helminth 
prevalence was less substantial (50%) than that in the cur-
rent study (70%). Interestingly, a study in Ecuador showed 
that albendazole treatment every 2 months over the course 
of 1 year, while reducing the prevalence of STH infection, 
did not result in an increased prevalence of atopy or aller-
gic symptoms [30]. In the Ecuadorian study, albendazole 
treatment resulted in a 70.4% (from 69.3 to 20.5%) reduc-
tion in helminth prevalence, similar to the finding in this 
study. However, despite a similar extent of reduction, the 
actual helminth prevalence after treatment in the Ecuador-
ian study was 8.5 times (50.5 vs. 5.9%) higher compared to 
our study, which might explain the lack of effect of de-
worming on the prevalence of SPT reactivity in Ecuador. 
The substantial decrease in the prevalence of helminth 
infections in our study, due to a biannual single-dose al-
bendazole MDA program, is rather surprising given that 
an earlier study [26] in adults in the same area showed that 
3 consecutive doses of albendazole at 3 monthly intervals 
are needed to achieve an 86.6% reduction in helminth 
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prevalence. However, in the present study the baseline 
prevalence of helminth infections was much lower at 
19.6% compared to the 41.7% reported in adults [26]. This 
indicates that biannual MDA might be sufficient in areas 
where there is a low prevalence of helminth infections. 
The strength of the current study is its longitudinal 
design; however, we acknowledge the limitations which 
include its small sample size, no control group, no data 
on allergen exposure or allergic symptoms, and no data 
on coinfections. 
In summary, the present study, carried out in school 
children in a rural area of Flores Island, Indonesia, showed 
that biannual MDA with albendazole resulted in a sig-
nificant decrease in the prevalence of STH infections 
which was accompanied by an increase in the prevalence 
of SPT reactivity to 2 of the most important allergens. 
Further studies in larger populations and in other endem-
ic areas are needed to confirm our results and further ex-
amine the effect of MDA with albendazole on the preva-
lence of allergic disorders.
Acknowledgement
We gratefully acknowledge Eka Setya Mulyawan, Dewi Ram-
liani Yani, and Selly for their time and tremendous support in the 
field. Also, we wish to express our gratitude to Stella de Jong, Nien-
ke de Vries, and Jilke Speulman for their contributions to collect-
ing and processing of the data. Most of all we are grateful for the 
participation of the children, parents, and teachers of the SD Kato-
lik Nangamboa Primary School in Nangapanda.
Disclosure Statement
We declare that we have no conflict of interest.
Funding Sources
Leiden University Medical Center. The sponsor of this study 
had no role in the study design, data collection, data analysis, data 
interpretation, or writing of this report. 
Author Contributions
Conception and design of the experiments: R.R., M.Y., T.S., 
and E.S. Data collection and experimentation: S.L.S., S.K.L.H., 
S.A.V., R.C.T., M.V., I.I.V., K.C.S., J.K.G., A.C.P., K.A., A.W., C.P., 
Y.D., D.L.T., and E.S. Interpretation of data and statistical analysis: 
S.L.S., S.K.L.H., S.A.V., R.C.T., M.V., I.I.V., K.C.S., J.K.G., K.A., 
C.P., Y.D., L.A.L., D.L.T., and E.S. Writing of this paper: S.L.S., 
S.K.L.H., S.A.V., R.C.T., M.V., I.I.V., K.C.S., J.K.G., L.A.L., D.L.T., 
and E.S. The corresponding author had full access to all of the data 
in this study and takes final responsibility for the decision to sub-
mit it for publication.
References
 1 Pawanker RC, Holgate ST, Lockey RF, edi-
tors. World Allergy Organization (WAO) 
White Book on Allergy 2011–2020. 2011.
 2 Anandan C, Nurmatov U, van Schayck OC, 
Sheikh A. Is the prevalence of asthma declin-
ing? Systematic review of epidemiological 
studies. Allergy. 2010 Feb; 65(2): 152–67.
 3 Nicolaou N, Siddique N, Custovic A. Allergic 
disease in urban and rural populations: in-
creasing prevalence with increasing urbaniza-
tion. Allergy. 2005 Nov; 60(11): 1357–60.
 4 Santiago HC, Nutman TB. Human Hel-
minths and Allergic Disease: The Hygiene 
Hypothesis and Beyond. Am J Trop Med Hyg. 
2016 Oct; 95(4): 746–53.
 5 Sitcharungsi R, Sirivichayakul C. Allergic dis-
eases and helminth infections. Pathog Glob 
Health. 2013 Apr; 107(3): 110–5.
 6 Strachan DP. Hay fever, hygiene, and house-
hold size. BMJ. 1989 Nov; 299(6710): 1259–60.
 7 Cooper PJ, Chico ME, Rodrigues LC, Or-
donez M, Strachan D, Griffin GE, et al. Re-
duced risk of atopy among school-age chil-
dren infected with geohelminth parasites in a 
rural area of the tropics. J Allergy Clin Immu-
nol. 2003 May; 111(5): 995–1000.
 8 Cooper PJ, Chico ME, Amorim LD, Sandoval 
C, Vaca M, Strina A, et al. Effects of maternal 
geohelminth infections on allergy in early 
childhood. J Allergy Clin Immunol. 2016 
Mar; 137(3): 899–906.e2.
 9 Lynch NR, Hagel I, Perez M, Di Prisco MC, 
Lopez R, Alvarez N. Effect of anthelmintic 
treatment on the allergic reactivity of children 
in a tropical slum. J Allergy Clin Immunol. 
1993 Sep; 92(3): 404–11.
10 van den Biggelaar AH, Rodrigues LC, van Ree 
R, van der Zee JS, Hoeksma-Kruize YC, Sou-
verijn JH, et al. Long-term treatment of intes-
tinal helminths increases mite skin-test reac-
tivity in Gabonese schoolchildren. J Infect 
Dis. 2004 Mar; 189(5): 892–900.
11 Haileamlak A, Lewis SA, Britton J, Venn AJ, 
Woldemariam D, Hubbard R, et al. Valida-
tion of the International Study of Asthma and 
Allergies in Children (ISAAC) and U.K. crite-
ria for atopic eczema in Ethiopian children. Br 
J Dermatol. 2005 Apr; 152(4): 735–41.
12 Davey G, Berhane Y, Duncan P, Aref-Adib 
G, Britton J, Venn A. Use of acetaminophen 
and the risk of self-reported allergic symp-
toms and skin sensitization in Butajira, Ethi-
opia. J Allergy Clin Immunol. 2005 Oct; 
116(4): 863–8.
13 Palmer LJ, Celedón JC, Weiss ST, Wang B, 
Fang Z, Xu X. Ascaris lumbricoides infec-
tion is associated with increased risk of 
childhood asthma and atopy in rural China. 
Am J Respir Crit Care Med. 2002 Jun; 
165(11): 1489–93.
14 Stein M, Greenberg Z, Boaz M, Handzel ZT, 
Meshesha MK, Bentwich Z. The Role of Hel-
minth Infection and Environment in the De-
velopment of Allergy: A Prospective Study of 
Newly-Arrived Ethiopian Immigrants in Is-
rael. PLoS Negl Trop Dis. 2016 Jan; 10(1): 
e0004208.
15 Hamid F, Wiria AE, Wammes LJ, Kaisar MM, 
Lell B, Ariawan I, et al. A longitudinal study 
of allergy and intestinal helminth infections 
in semi urban and rural areas of Flores, Indo-
nesia (ImmunoSPIN Study). BMC Infect Dis. 
2011 Apr; 11(1): 83.
16 Smits HH, Everts B, Hartgers FC, Yazdan-
bakhsh M. Chronic helminth infections pro-
tect against allergic diseases by active regula-
tory processes. Curr Allergy Asthma Rep. 
2010 Jan; 10(1): 3–12.
Staal et al.Int Arch Allergy Immunol 2018;177:192–198198
DOI: 10.1159/000490952
17 McSorley HJ, O’Gorman MT, Blair N, Suther-
land TE, Filbey KJ, Maizels RM. Suppression 
of type 2 immunity and allergic airway in-
flammation by secreted products of the hel-
minth Heligmosomoides polygyrus. Eur J Im-
munol. 2012 Oct; 42(10): 2667–82.
18 Beasley R; The International Study of Asthma 
and Allergies in Childhood (ISAAC) Steering 
Committee. Worldwide variation in preva-
lence of symptoms of asthma, allergic rhino-
conjunctivitis, and atopic eczema: ISAAC. 
Lancet. 1998 Apr; 351(9111): 1225–32.
19 World Bank and Health in Indonesia [cited 
2017 Sept 11]. Available from: http://www.
worldbank.org/en/country/indonesia/brief/
world-bank-and-health-in-indonesia.
20 Wiria AE, Hamid F, Wammes LJ, Kaisar MM, 
May L, Prasetyani MA, et al. The effect of 
three-monthly albendazole treatment on ma-
larial parasitemia and allergy: a household-
based cluster-randomized, double-blind, pla-
cebo-controlled trial. PLoS One. 2013; 8(3): 
e57899.
21 Cogill B. Anthropometric Indicators Mea-
surement Guide 2003. Available from: http://
www.fantaproject.org/sites/default/files/re-
sources/anthropometry-2003-ENG.pdf.
22 Katz N, Chaves A, Pellegrino J. A simple de-
vice for quantitative stool thick-smear tech-
nique in Schistosomiasis mansoni. Rev Inst 
Med Trop Sao Paulo. 1972 Nov-Dec; 14(6): 
397–400.
23 Wiria AE, Prasetyani MA, Hamid F, Wammes 
LJ, Lell B, Ariawan I, et al. Does treatment of 
intestinal helminth infections influence ma-
laria? Background and methodology of a lon-
gitudinal study of clinical, parasitological and 
immunological parameters in Nangapanda, 
Flores, Indonesia (ImmunoSPIN Study). 
BMC Infect Dis. 2010 Mar; 10(1): 77.
24 Ortu G, Assoum M, Wittmann U, Knowles S, 
Clements M, Ndayishimiye O, et al. The im-
pact of an 8-year mass drug administration 
programme on prevalence, intensity and co-
infections of soil-transmitted helminthiases 
in Burundi. Parasit Vectors. 2016 Sep; 9(1): 
513.
25 WHO. Intestinal worms strategy [cited 2018 
Jan 20]. Available from: http://www.who.int/
intestinal_worms/strategy/en/.
26 Tahapary DL, de Ruiter K, Martin I, Brienen 
EA, van Lieshout L, Cobbaert CM, et al. Effect 
of Anthelmintic Treatment on Insulin Resis-
tance: A Cluster-Randomized, Placebo-Con-
trolled Trial in Indonesia. Clin Infect Dis. 
2017 Sep; 65(5): 764–71.
27 Knopp S, Mohammed KA, Speich B, Hatten-
dorf J, Khamis IS, Khamis AN, et al. Albenda-
zole and mebendazole administered alone or 
in combination with ivermectin against 
Trichuris trichiura: a randomized controlled 
trial. Clin Infect Dis. 2010 Dec; 51(12): 1420–8.
28 Keiser J, Utzinger J. Efficacy of current drugs 
against soil-transmitted helminth infections: 
systematic review and meta-analysis. JAMA. 
2008 Apr; 299(16): 1937–48.
29 de Ruiter K, Tahapary DL, Wammes LJ, Wir-
ia AE, Hamid F, van Lieshout L, et al. The ef-
fect of three-monthly albendazole treatment 
on Th2 responses: differential effects on IgE 
and IL-5. Parasite Immunol. 2017 Jun; 39(6): 
e12428.
30 Cooper PJ, Chico ME, Vaca MG, Moncayo 
AL, Bland JM, Mafla E, et al. Effect of alben-
dazole treatments on the prevalence of atopy 
in children living in communities endemic for 
geohelminth parasites: a cluster-randomised 
trial. Lancet. 2006 May; 367(9522): 1598–603.
31 Bhargava A, Jukes M, Lambo J, Kihamia CM, 
Lorri W, Nokes C, et al. Anthelmintic treat-
ment improves the hemoglobin and serum 
ferritin concentrations of Tanzanian school-
children. Food Nutr Bull. 2003 Dec; 24(4): 
332–42.
32 Kung’u JK, Goodman D, Haji HJ, Ramsan M, 
Wright VJ, Bickle QD, et al. Early helminth 
infections are inversely related to anemia, 
malnutrition, and malaria and are not associ-
ated with inflammation in 6- to 23-month-old 
Zanzibari children. Am J Trop Med Hyg. 2009 
Dec; 81(6): 1062–70.
33 Sittipo P, Lobionda S, Lee YK, Maynard CL. 
Intestinal microbiota and the immune system 
in metabolic diseases. J Microbiol. 2018 Mar; 
56(3): 154–62.
34 Flandroy L, Poutahidis T, Berg G, Clarke G, 
Dao MC, Decaestecker E, et al. The impact of 
human activities and lifestyles on the inter-
linked microbiota and health of humans and 
of ecosystems. Sci Total Environ. 2018 Jun; 
627: 1018–38.
35 Postler TS, Ghosh S. Understanding the Ho-
lobiont: How Microbial Metabolites Affect 
Human Health and Shape the Immune Sys-
tem. Cell Metab. 2017 Jul; 26(1): 110–30.
36 van den Biggelaar AH, van Ree R, Rodrigues 
LC, Lell B, Deelder AM, Kremsner PG, et al. 
Decreased atopy in children infected with 
Schistosoma haematobium: a role for parasite-
induced interleukin-10. Lancet. 2000 Nov; 
356(9243): 1723–7.
